Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioCision Announces Launch of HistoMailer™

Published: Monday, December 05, 2011
Last Updated: Monday, December 05, 2011
Bookmark and Share
The HistoMailer ensures simple, reliable transfer of tissue samples from the clinic to the laboratory.

BioCision, LLC has announced the launch of a new product - the HistoMailer - for safely sending tissue blocks for laboratory analysis.

The HistoMailer represents the first in a series of products designed to specifically address the need for safe, reliable transfer of samples between laboratories.

“We immediately recognized the need for a reliable tool to ship paraffin-embedded tissue blocks, which can melt during transport if not packaged correctly,” said Hugh Douglas, BioCision’s Chief Operating Officer.

Douglas continued, “The HistoMailer is a great fit with our expanding product portfolio of integrated solutions for biomedical sample handling from preparation to shipping. In the coming months, we will be introducing additional products to serve the specific tissue processing needs of clinical histology and pathology labs.”

The HistoMailer was originally developed by technicians at Mayo Medical Laboratories, which receives approximately 30,000 specimens per day from hospitals across the country.

According to Mayo Clinic Operations Coordinator Jeff Wills, “The HistoMailer provides end users with a value add when transporting lab specimens. The container is a full-circle tool, from start to finish and provides Mayo with the opportunity to become more green. Mayo’s Department of Laboratory Medicine and Pathology is currently using the technology, along with over one-thousand users across our client base.” Wills is also an inventor of the HistoMailer technology.

“Working with leading academic institutions to develop new tools and products is an important part of BioCision’s overall strategy to best serve biomedical researchers and clinicians,” said BioCision’s CEO Rolf Ehrhardt, MD, PhD.

BioCision specializes in benchtop products that ensure consistency, reproducibility and standardization of laboratory samples, with applications in drug discovery, and basic and clinical research.

Users benefit from high sample reproducibility and consistency - experiment to experiment, lab to lab and research/clinical site to site.

Mayo Clinic and Mr. J. Willis have a financial interest in the technology referenced in this news release.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioCision to Develop Controlled-Rate Cell Freezing Systems for Cook Regentec Cell Therapy Vials
BioCision and Cook ink exclusive deal to combine technologies to standardize cell cryopreservation in closed-system vials.
Wednesday, July 29, 2015
BioCision to Collaborate with Celgene Cellular Therapeutics
Companies to collaborate on standardizing and de-risking cell thawing process for a Phase 2 cell therapy for the treatment of diabetic foot ulcers.
Wednesday, June 03, 2015
Brooks Automation, BioCision Announce Equity Investment and Strategic Collaboration
Brooks invests $4 million into BioCision to build strategic alignment in biobanking and sample handling.
Monday, March 24, 2014
BioCision Announces Two New U.S. Patents for Thermo-Conductive Products
New patents awarded for CoolSink® Plate Modules and ThermalTray™ Platforms.
Thursday, June 20, 2013
BioCision’s CoolProduct range now available from SANYO
BioCision, LLC have announced the signing of a product distribution agreement with SANYO E&E Europe BV, SANYO’s biomedical division in Europe. SANYO will be marketing the entire CoolProduct portfolio – a modular system of benchtop laboratory tools based on BioCision’s patented technology for temperature change and control of benchtop biomedical samples.
Wednesday, November 17, 2010
Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!